Donepezil Tablet
Product Images NDC 82009-119

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Donepezil (NDC 82009-119). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezilfigure10 (Donepezilfigure10)

A line chart comparing the cumulative percentage of patients versus ADCS-ADL change from baseline for Donepezil Hydrochloride 10 mg/day and placebo groups. The x-axis represents ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients, with two distinct curves marked by symbols for each group.*

FDA Label Image

Donepezilfigure8 (Donepezilfigure8)

A cumulative percentage plot showing the change from baseline in Severe Impairment Battery (SIB) scores for patients treated with Donepezil hydrochloride 10 mg/day compared to placebo. The x-axis represents the SIB change from baseline, and the y-axis shows the cumulative percentage of patients.*

FDA Label Image

Figure1 (Figure1)

A line graph depicting the ADAS-cog change from baseline over weeks of drug treatment for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis shows the mean change with standard error, indicating clinical improvement above baseline and clinical decline below. The x-axis spans 0 to 30 weeks with a placebo treatment period shaded from 24 to 30 weeks, showing response trends over time for each group.*

FDA Label Image

Figure2 (Figure2)

A cumulative percentage of patients chart showing change from baseline in cognitive function scores (ADAS cog) for Donepezil Hydrochloride tablets at 5 mg/day and 10 mg/day doses compared to placebo. The graph plots change on the x-axis against cumulative percentage of patients on the y-axis, illustrating treatment effects over the baseline measurements.*

FDA Label Image

Figure3 (Figure3)

A bar chart comparing the CIBIC-Plus Rating outcomes in patients treated with Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The horizontal axis shows categories from Markedly Improved to Markedly Worse, and the vertical axis indicates the percentage of patients in each category. The chart illustrates the distribution of patient responses for each treatment group.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting the change in ADAS-cog scores from baseline over 12 weeks of drug treatment for Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis shows ADAS-cog score change, with positive values indicating clinical improvement and negative values indicating clinical decline. The x-axis shows weeks of drug treatment from 0 to 12. Error bars indicate variability in measurements for each group.*

FDA Label Image

Figure5 (Figure5)

A cumulative percentage curve chart depicting patient response to Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo based on change from baseline in ADAS cognitive scores. The chart shows progression in cognitive change, with a legend and a table summarizing treatment group percentages at specific change points (-7, -4, 0).*

FDA Label Image

Figure6 (Figure6)

A bar chart depicting the distribution of patients by CIBIC-plus Rating, comparing Donepezil Hydrochloride at 10 mg/day, 5 mg/day, and Placebo. The x-axis shows categories from Markedly Improved to Markedly Worse, and the y-axis represents the percentage of patients. Three colored bars represent each treatment group's patient percentages across the rating categories.*

FDA Label Image

Figure7 (Figure7)

A line graph depicting the SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment. It compares Donepezil Hydrochloride 10 mg/day and placebo, showing clinical improvement or decline across time points at 0, 3, and 6 months.*

FDA Label Image

Figure9 (Figure9)

A line graph depicting the change from baseline in ADCS-ADL scores over six months of drug treatment. It compares Donepezil Hydrochloride 10 mg daily to a placebo, showing clinical improvement and decline on the vertical axis and months of treatment on the horizontal axis, with error bars illustrating variability.*

FDA Label Image

10mg-500s (Donepezil 10mg 500s Count Label)

Donepezil Hydrochloride Tablets, USP 10 mg film-coated tablets label by Quallent Pharmaceuticals Health LLC. The label indicates a quantity of 500 tablets, prescription only, with storage instructions at controlled room temperature and moisture protection. It includes a barcode and manufacturer details from Grand Cayman and India.*

FDA Label Image

5mg-500s (Donepezil 5mg 500s Count Label)

Donepezil Hydrochloride Tablets USP 5 mg oral tablets packaging label by Quallent Pharmaceuticals Health LLC. The label indicates 500 tablets per package, prescription use only, and provides storage instructions, dosage advice to see package insert, and contact information. It includes a barcode and manufacturing details from Quallent and Hetero Labs Limited in India.*

FDA Label Image

Logo (Quallent Logo)

FDA Label Image

Structure (Structure)

Chemical structure diagram of Donepezil hydrochloride, showing its molecular framework including aromatic rings, piperidine ring, methoxy groups, and hydrochloride association.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.